Complete Remissions in Metastatic Breast Cancer Treated with Combination Drug Therapy

Sewa S. Legha(The University of Texas MD Anderson Cancer Center), E. J. Freireich, Aman U. Buzdar(The University of Texas MD Anderson Cancer Center), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Edmund A. Gehan(Georgetown University), Terry L. Smith(Virginia Commonwealth University), Kenneth D. Swenerton, G. P. Bodey(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)
Annals of Internal Medicine
December 1, 1979
10.7326/0003-4819-91-6-847
Cited by 92

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
|Journal of neurosurgery|1978|1.7k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k